Generics

Generic firms working on Paxlovid access for low-, middle-income countries
The manufacturers have signed agreements with the Medicines Patent Pool to make and supply the generic version of Pfizer’s oral COVID-19 treatment Paxlovid.
Upsher-Smith makes leadership changes
Taku Nakaoka is now chairman and CEO of Upsher-Smith and Rich Fisher, senior vice president of corporate strategy, is president and COO.

Aurobindo receives FDA OK for generic Sabril
The medication is indicated as adjunctive therapy for adults and pediatric patients aged 2 years old and older with refractory complex partial seizures.
Camber launches generic Reyataz
The medication is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients.
Hikma updates expected launch of authorized generic Xyrem
Hikma now conservatively assumes it will launch its authorized generic on Jan. 1, 2023.
FDA grants Glenmark tentative nod for generic Enstilar
Enstilar foam had a market value of roughly $115.2 million for the 12-month period ending March 2022, according to IQVIA.
FDA gives Lupin clearance for 2 generics
The company received approval for Iloperidone tablets and pregabalin capsules.
Alembic receives FDA nod for generic Abreva
Docosanol cream 10% (OTC) had a market value of roughly $60 million for the 12 months ending December 2021, according to IQVIA.
Xiromed intros progesterone injection
The medication is the generic of progesterone injection, which is used to restore normal menstrual periods or treat abnormal bleeding due to low hormone levels.
Advanz Pharma names new CEO
Steffen Wagner joins Advanz from Stada, where he was a member of the Global Executive Committee and responsible for the European market.
Meitheal Pharmaceuticals joins AAM
Meitheal primarily specializes in the development, manufacture, procurement and sale of generic injectable pharmaceuticals.
FDA gives Breckenridge tentative OK for generic Pradaxa
Pradaxa had a market value of $455 million during the 12 months ending February 2022, according to industry data, the company said.
Lundbeck names CFO, head of corporate functions
Joerg Hornstein has been named chief financial officer and a member of Lundbeck’s executive management.
Teva settles patent dispute with Lupin on generic Austedo
Lupin will have a license to sell its generic product beginning April 2033 or earlier under certain circumstances.

News and information on generic drugs sold in retail pharmacies, as well as their suppliers.